Products

Nexavar® (sorafenib), is an oral, novel multiple kinase inhibitor that targets proteins involved in both tumor cell proliferation and angiogenesis (the formation of new blood vessels to support cancer cell growth).

Approved Uses

  • In December 2005, the FDA approved Nexavar for advanced renal cell carcinoma (RCC), or kidney cancer.
  • In July 2006, Nexavar was approved by the European Medicines Agency (EMEA) for the treatment of patients with advanced RCC who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
  • Nexavar is currently approved in more than 90 countries for the treatment of advanced kidney cancer.
  • In October 2007, Nexavar was approved by the European Commission for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer.
  • In November 2007, Nexavar was approved by FDA for the treatment of patients with unresectable HCC.
  • Nexavar is currently approved in more than 90 countries for the treatment of HCC.

Nexavar is the only approved drug shown to inhibit the enzyme RAF kinase, which is a critical component of the RAS pathway — an important cascade of chemical signals that controls cell division. Abnormal activation of the RAS pathway is believed to play an integral role in the genesis of many cancers.

Additionally, Nexavar inhibits VEGFR-1, -2 and -3, and PDGFR-ß, key receptors of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), which play important roles in angiogenesis. Nexavar also inhibits other tyrosine kinases such as c-KIT, RET and FLT-3.

Partner Status

Onyx and Bayer are developing and marketing Nexavar under collaboration and co-promotion agreements. Onyx and Bayer each fund 50 percent of the development costs for Nexavar worldwide, excluding Japan, where Bayer funds all product development. With Bayer, Onyx is co-promoting Nexavar in the United States and sharing equally in any profits or losses. Outside of the U.S., Bayer has exclusive marketing rights and Onyx shares profits 50/50, excluding Japan, where Onyx receives a royalty.

 


Important Safety Considerations

Hypertension may occur early in the course of treatment. Monitor blood pressure weekly during the first 6 weeks and periodically thereafter and treat, as required.

An increased risk of bleeding may occur following Nexavar administration. If bleeding necessitates medical intervention, consider discontinuation of Nexavar.

Cardiac ischemia and/or myocardial infarction may occur. Temporary or permanent discontinuation of Nexavar should be considered in patients who develop cardiac ischemia and/or myocardial infarction.

Gastrointestinal perforation was an uncommon adverse reaction and has been reported in less than 1% of patients taking Nexavar.

Most common adverse reactions reported for Nexavar-treated patients vs placebo-treated patients in unresectable HCC, respectively, were: diarrhea (55% vs 25%), fatigue (46% vs 45%), abdominal pain (31% vs 26%), weight loss (30% vs 10%), anorexia (29% vs 18%), nausea (24% vs 20%), and hand-foot skin reaction (21% vs 3%). Grade 3/4 adverse reactions were 45% vs 32%.

Most common adverse reactions reported for Nexavar-treated patients vs placebo-treated patients in advanced RCC, respectively, were: diarrhea (43% vs 13%), rash/desquamation (40% vs 16%), fatigue (37% vs 28%), hand-foot skin reaction (30% vs 7%), alopecia (27% vs 3%),and nausea (23% vs 19%). Grade 3/4 adverse reactions were 38% vs 28%.

Hand-foot skin reaction and rash are common and management may include topical therapies for symptomatic relief. In cases of any severe or persistent adverse reactions, temporary treatment interruption, dose modification, or permanent discontinuation of Nexavar should be considered. Temporary interruption of Nexavar therapy is recommended in patients undergoing major surgical procedures.

Elevations in serum lipase and reductions in serum phosphate of unknown etiology have been associated with Nexavar. Caution is recommended when administering Nexavar with compounds that are metabolized/eliminated predominantly by the UGT1A9 pathway, UGT1A1 pathway (eg, irinotecan), doxorubicin, docetaxel, fluorouracil, and substrates of CYP2B6 and CYP2C8, and CYP3A4 inducers. Patients taking concomitant warfarin should be monitored regularly for changes in prothrombin time, INR, or clinical bleeding episodes.

Women of childbearing potential are advised to avoid becoming pregnant and against breastfeeding.